ProtoKinetix

ProtoKinetix EBIT Growth

The Year-over-Year EBIT Growth of ProtoKinetix (PKTX) as of Nov 19, 2026 is -26.58 %. In the previous year, Year-over-Year EBIT Growth was 15.26 % — a change of -274.16% (lower).

EBIT Growth

-26.58 %

YoY

-274.16%

Last updated:

Year-over-Year EBIT Growth of ProtoKinetix is 2025 -26.58 % . Year-over-Year EBIT Growth of ProtoKinetix was 2024 15.26 % . It decreases by -274.16% lower compared to the previous year.

The ProtoKinetix EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
19.57 USD
Jan 1, 2019
-245.21 USD
Jan 1, 2020
-82.09 USD
Jan 1, 2021
69.53 USD
Jan 1, 2022
20.61 USD
Jan 1, 2023
80.15 USD
Jan 1, 2024
15.26 USD
Jan 1, 2025
-26.58 USD
The ProtoKinetix EBIT Growth history
YEAREBIT GrowthYoY
-26.58 %-274.16%
15.26 %-80.96%
80.15 %+288.90%
20.61 %-70.36%
69.53 %-184.70%
-82.09 %-66.52%
-245.21 %-1,352.80%
19.57 %+2,259.20%
0.83 %-103.92%
-21.19 %-90.69%
-227.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Year-over-Year EBIT Growth of ProtoKinetix is -26.58 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ProtoKinetix

All Key Metrics — ProtoKinetix